Combination therapy improves survival time for patients with advanced liver cancer
Saturday, November 20, 2010 - 01:20
in Health & Medicine
Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared to patients who received treatment with doxorubicin alone, according to a new study.